Confidence in Concept
The Confidence in Concept scheme provides awards of £300k-£1m to institutions, to be used flexibly to support the earliest stages of multiple translational research projects.
Pre-clinical and clinical development of therapies, devices and diagnostics.
The “Challenge Grants” initiative will support ambitious, challenge-led studies of disease mechanisms in humans.
Global health trials
The MRC funds clinical trials through the Efficacy and Mechanism Evaluation programme (EME) and Global Health programme.
For the purposes of obtaining funding from the MRC, methodology research includes methods development to underpin the biomedical sciences, experimental medicine, clinical trials, population health sciences, health services research and health policy.
Collaboration Agreement (MICA)
If you are considering establishing a collaboration with an industrial partner(s), you and your potential collaborator(s) are advised to refer to the guidance on MRC Industry Collaboration Agreement (MICAs).
Research Grant (NIRG)
Support for clinical and non-clinical researchers while they establish themselves as independent principal investigators.
New joint funding
arrangements for late phase clinical
The MRC remains committed to supporting clinical trials. This page describes the changes coming into effect early 2008.
For collaborative activities that add value to existing research or helps galvanise researchers in a particular field.
Provides larger, longer term, renewable programme funding to help the medical science community think bigger.
Our main scheme for supporting biomedical science in UK universities and NHS Trusts.
The Hubs in Trials
In 2009, the MRC established the MRC Network of Hubs for Trials Methodology Research to create a regionally distributed resource to improve the design, implementation, analysis, interpretation and reporting of clinical trials.
Translational stem cell
research - Response mode funding
Part of the MRC/NIHR single health research strategy.
Next Generation Optical
Pump-priming investment of up to £18 million (£15m MRC, £2m BBSRC and £1m EPSRC) is available to support 10 or more strategic and innovative partnerships for up to five years.
Joint Global Health
Trials scheme – launch of third call
UK Department for International Development, MRC and Wellcome Trust scheme to fund global health trials to generate new knowledge about interventions that will contribute to improvement of health in low and middle income countries.
Expressions of interest
for research consortia to
establish a new cohort for intellectual disabilities
The purpose of the MRC Call for Expression of Interest (EoI) is to gauge the likely interest in establishing a new cohort for research on intellectual disabilities.
UK Regenerative Medicine
To fund a limited number of interdisciplinary research hubs based on scientific excellence and with the critical mass to address the key developmental challenges for the field.
Mechanisms of Disease call for proposals
The MRC and AstraZeneca have worked together to provide access for UK academic researchers to a high-quality collection of AstraZeneca compounds.
Stratified Medicine -
Call for proposals for
disease-focused partnerships to stratify disease for
Researchers are now invited to submit outline proposals for funding for the development of disease-focussed consortia to stratify disease.
Working with industry –
developing a consortium to
While the MRC has significant research investments in obesity and metabolic disease, there are opportunities for further collaboration between industry. Investigators are now invited to take part in developing a consortium to stratify diabetes.
Joint Synthetic Biology
Researchers are invited to apply for funding from a new Joint Synthetic Biology Initiative, which has made up to £2.4 million available from the MRC, BBSRC, Dstl, and EPSRC.
Opportunities to work in
the new Research Complex at
Applications for the opportunity of being one of the initial occupants of the Research Complex are invited to the 2012 deadlines of current MRC funding schemes.
European and developing
countries clinical trials
EDCTP. To accelerate development of new or improved drugs and vaccines, with a focus on phase II and III clinical trials and on Sub-Saharan Africa.
Please visit: www.mrc.ac.uk for further information